The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) provide updated public health assessments on the use of the newly licensed adapted COVID-19 vaccines to support the planning of autumn/winter vaccination campaigns.
This statement is based on an assessment of current epidemiological trends and available scientific evidence. National Immunisation Technical Advisory Groups (NITAGs) will make final national recommendations on the use of COVID-19 vaccines, taking into account the epidemiological situation in their countries.
On 1 September 2022, Comirnaty Original/Omicron BA.1 and Spikevax Bivalent Original/Omicron BA.1 vaccines were licensed in the EU following positive opinions from the EMA. Both vaccines incorporate the spike protein of the Omicron BA.1 variant and the original SARS-CoV-2 strain. As requested by the International Coalition of Medicines Regulatory Authorities (ICMRA COVID-19 Omicron variant workshop | International Coalition of Medicines Regulatory Authorities (ICMRA)) clinical trials were conducted which showed that the new customized vaccines provide superior amounts of neutralizing antibodies against the Omicron BA.1 variant compared to existing monovalent vaccines based on the original strain. In addition, the antibodies produced by the custom vaccines appear to be able to more effectively neutralise other lines and subtypes of the Omicron variant, including BA.2, BA.2.75 and BA.5, compared to existing monovalent vaccines. It is currently not known to what extent these improvements in the immune response to Omicron variants will translate into increased protection. Data from clinical trials with adapted bivalent Omicron vaccines show a safety profile, based on measures of local and systemic reactogenicity, that is very similar compared to the original monovalent vaccines.
Recommended population groups for booster doses
While regulatory approval allows the use of these customized vaccines from age 12 years and older, upcoming fall/winter vaccination campaigns should prioritize boosting those at risk of progression to severe disease following infection due to risk factors, such as the elderly (e.g.e.g. over 60 years of age), immunocompromised persons and persons with underlying diseases and pregnant women. In addition, residents and staff in long-term care facilities should also be prioritised. Healthcare workers should also be considered for additional booster doses with these vaccines, as it may have been a long time since their last dose (e.g., in some cases a year or more). The purpose of vaccinating healthcare workers will be to provide some protection against new infection, given their increased exposure, and to maximise the ability of health systems to function properly in the event of a significant new wave of SARS-CoV-2 later this year. Early vaccination is more important than the choice of vaccine type for booster dose. Existing monovalent vaccines based on the original strain still provide protection against severe disease and should be considered in case adapted vaccines are not yet available.
Inter-dose interval
Regulatory approval supports the administration of additional booster doses with an interval of 3 months after the previous dose, if necessary. However, longer intervals may be considered in vaccination campaigns, based on actual evidence of recovery and maintenance of a high level of protection against severe disease for at least 4 months after the first booster dose. Intervals longer than 4 months may be considered, according to evidence of a stronger immune response obtained with longer intervals between doses, but this has to be balanced against the attenuation of protection and the local epidemiological situation. Priority for booster doses should be given to persons from vulnerable groups who received their last vaccination more than 6 months previously. Timing of booster vaccination just before or at the beginning of the peak virus circulation period, as is usually expected with respiratory viruses at the beginning or during the autumn/winter season, would be highly desirable. The combination of COVID-19 and influenza vaccination campaigns should also be considered. Although it is still unknown how the virus will evolve in the coming months, it can be expected that in the long term, annual booster vaccination could be necessary at the beginning of the autumn/winter season, just as for influenza.
Vaccination of people with recent SARS-CoV-2 infection
Studies examining the combined effect of naturally acquired immunity and vaccine-induced immunity clearly show an additional protection benefit for those with hybrid immunity. Evidence to date also shows that the variant-specific protection against infections and serious diseases provided by hybrid immunity fades at a slower rate than protection provided by vaccine-induced or infection-induced immunity alone, although the strength and duration of protection may depend on several factors such as the type of vaccine, the time since vaccination or infection, the type of SARS-CoV-2 variant that caused the infection and host-related factors. Therefore, consideration may be given to the recommendation that persons with initial vaccination and recent SARS-CoV-2 infection wait at least 3 months or preferably even more than 4 months after infection before receiving a booster dose.
Use of customized vaccines for booster doses
Customized vaccines are currently licensed for use as booster doses only in individuals who have completed at least the initial regimen/primary vaccination, regardless of which vaccines were used in that regimen. The use of customized vaccines should for the time being remain limited to their use as booster doses. Existing monovalent vaccines incorporating the original strain will be used for effective primary vaccination and to induce adequate initial protection in individuals who have not yet been vaccinated.
Additional vaccine options
Following the approval of Omicron BA.1/ Original, other products incorporating either the Omicron BA.4/5 and the original strains or the Beta variant of concern are being evaluated for possible rapid approval, thus offering a diversified portfolio of options for vaccination campaigns later this year. Due to the uncertainties surrounding which variants will be released in the autumn and winter period, it is not possible to predict whether significant differences in protection between vaccines could arise. In general, the already licensed adapted vaccines as well as upcoming ones, if approved, are expected to broaden immunity against variants of concern that have recently emerged and been released, particularly the Omicron variant and related sub-variants.
As the clinical studies supporting the approval of these adapted vaccines have focused on collecting data on safety and immunogenicity, it is important to note that real-world data will be necessary to measure t